NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 3 நாட்களுக்கு முன்இன்று 0 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Balaji Amines Q2 FY27 Concall: Consolidated PAT Surges 82% YoY to ₹67 Cr, Revenue Up 36%
Balaji Amines released its Q2 FY27 earnings call transcript, highlighting strong operational performance with consolidated revenue rising 36% YoY to ₹472 crore. Net profit for the quarter jumped 82% YoY to ₹67 crore, while EBITDA grew 58% YoY to ₹106 crore with margins expanding to 22%. Management noted commercial production has commenced at its upgraded Acetonitrile plant (1,440 tons/month capacity) and PESO road tanker valve approvals were received for Dimethyl Ether (DME). All ongoing capital expansion projects across Balaji Amines and subsidiary BSCL are targeted for completion by the end of FY27.
உச்சம் நம்பிக்கை
என்ன மாறியதுSubmission of the verbatim transcript for the Q2 FY27 earnings conference call held on November 4, 2026.
ஏன் இது முக்கியம்Provides detailed management commentary on the timeline for capital projects concluding in FY27, margin sustainability, and commercial ramp-up in Acetonitrile and DME.
📅 குறுகிய காலம்Earnings numbers were previously disclosed, but details on volume recovery (+13.5% QoQ) and ACN/DME commercialization provide positive sentiment for operational momentum.
📈 நீண்ட காலம்As major capex phases conclude by end of FY27, management targets 80-90% utilization across plants in FY28, shifting focus from capital outlay to free cash flow generation.
⚠ அபாய எச்சரிக்கைகள்
Potential logistics delays affecting equipment erection at BSCL Unit-2
Regulatory reliance on pending PESO approvals and BPCL blending clearances to achieve >90% DME utilization
👀 கவனிக்க வேண்டியவை
Track capacity ramp-up and utilization rates for Acetonitrile and DME in H2 FY27, as well as PESO approvals and BPCL LPG blending permissions for DME.
Balaji Amines Q2 FY27 Consolidated PAT Surges 82% YoY to ₹67 Cr; Revenue Up 36% to ₹472 Cr
Balaji Amines reported strong Q2 FY27 performance, with consolidated revenue rising 35.8% YoY to ₹472 crore and PAT surging 81.9% YoY to ₹67 crore. EBITDA grew 58.5% YoY to ₹106 crore, maintaining a healthy margin of 22% despite supply chain headwinds. For H1 FY27, consolidated PAT doubled to ₹146 crore on revenue of ₹933 crore. Expansion remains intensive, with ₹516.71 crore in ongoing CWIP across BSCL and other units targeting commercialization by Q4 FY27.
உச்சம் நம்பிக்கை
என்ன மாறியதுBalaji Amines released its Q2 FY27 investor presentation, disclosing detailed financial results, operating margins, and project pipeline status.
ஏன் இது முக்கியம்Demonstrates robust earnings recovery from FY26 levels with expanding operating margins (22% vs 19% YoY), supported by new commercialized capacities like Acetonitrile.
Consolidated Q2 FY27 Revenue: ₹472 கோடிConsolidated Q2 FY27 PAT: ₹67 கோடிConsolidated Q2 FY27 EBITDA Margin: 22%BSCL Capital Work-in-Progress: ₹438.17 கோடிBSCL CWIP vs Net Worth: ~23.2%
📅 குறுகிய காலம்Positive sentiment likely due to substantial YoY growth in earnings and commercialization of the upgraded Acetonitrile plant, though sequentially PAT dipped 13.6% from Q1 FY27.
📈 நீண்ட காலம்Commissioning of high-value downstream derivatives (HCN, NaCN, EDTA, DME, NMM) through FY27 could structurally improve product mix, realizations, and long-term operating leverage.
⚠ அபாய எச்சரிக்கைகள்
External supply chain delays and raw material availability impacting volume growth
Execution and commissioning delays in large CWIP projects at BSCL
👀 கவனிக்க வேண்டியவை
Track the commissioning timelines of the BSCL Unit-I brownfield expansion and Unit-II HCN/NaCN/EDTA project slated for Q4 FY27, as well as customer ramp-up for DME.
Balaji Amines Q2 FY27 Standalone PAT Jumps 118% YoY to ₹68.73 Cr; Revenue Up 38% to ₹427.80 Cr
Balaji Amines reported a sharp 118.5% YoY rise in standalone net profit to ₹68.73 crore for Q2 FY27 (ended September 30, 2026), compared to ₹31.45 crore in Q2 FY26. Standalone revenue from operations grew 38.4% YoY to ₹427.80 crore from ₹309.20 crore, though remaining flat sequentially against ₹427.38 crore in Q1. For H1 FY27, net profit expanded 97.7% YoY to ₹140.87 crore on revenue of ₹850.54 crore. Separately, the Board noted a Warning-cum-Advisory letter issued by SEBI and advised management to ensure prompt regulatory compliance.
உச்சம் நம்பிக்கை
என்ன மாறியதுBalaji Amines declared strong Q2 FY27 standalone financial results showing over 100% profit growth YoY and acknowledged receipt of a regulatory advisory letter from SEBI.
ஏன் இது முக்கியம்The earnings display strong operational recovery with H1 revenue already tracking over 55% of full-year FY26 levels, reflecting ramp-up of expanded capacities and improved realizations.
📅 குறுகிய காலம்Strong year-on-year earnings growth provides fundamental support, though sequential operating margins slightly narrowed relative to Q1 FY27.
📈 நீண்ட காலம்Sustained revenue growth aligns with new product commercialization and Greenfield Unit 4 capex, strengthening earnings potential if demand from end-user pharma/agri industries stays resilient.
⚠ அபாய எச்சரிக்கைகள்
SEBI Warning-cum-Advisory Letter noted by the Board
Slight sequential drop in PAT from ₹72.14 crore in Q1 to ₹68.73 crore in Q2
Raw material volatility risks in chemical intermediate manufacturing
👀 கவனிக்க வேண்டியவை
Monitor management commentary on gross margin sustainability and volume trajectory across pharma/agri end-user segments, alongside any regulatory follow-up disclosures regarding SEBI's advisory letter.
Balaji Amines Commences Acetonitrile Production, Expands Capacity to 1,440 TPM
Balaji Amines Limited has announced the successful commencement of commercial production at its Acetonitrile (ACN) plant with effect from September 24, 2026. The plant, located at Unit-III in Chincholi MIDC, Solapur, incorporates advanced technology under the company's expansion and modernisation programme. Following this commissioning, the total installed capacity for Acetonitrile has been enhanced to 1,440 tonnes per month (TPM). The product will cater to both domestic and international markets, primarily serving pharmaceutical and chemical synthesis applications.
உச்சம் நம்பிக்கை
என்ன மாறியதுBalaji Amines has commissioned upgraded Acetonitrile production lines at Solapur, boosting installed capacity to 1,440 TPM.
ஏன் இது முக்கியம்Acetonitrile is a critical solvent for the pharmaceutical industry; higher capacity with improved process efficiency can support volume growth on top of TTM revenues of ₹1,523 Cr.
Enhanced installed capacity: 1,440 TPMCommercial production start date: 24th செப்டம்பர், 2026TTM Revenue Context: ₹1523 கோடி
📅 குறுகிய காலம்Positive sentiment driver as an ongoing expansion project transitions into active commercial production without delays.
📈 நீண்ட காலம்Aids import substitution and pharmaceutical demand capture, contributing incremental volumes to support management's broader growth initiatives across Unit 4 and BSCL.
⚠ அபாய எச்சரிக்கைகள்
Raw material price volatility (e.g., acetic acid/ammonia derivatives)
Global price competition and dumping risks in Acetonitrile from overseas producers
👀 கவனிக்க வேண்டியவை
Track capacity utilisation ramp-up and pricing trends for Acetonitrile in the upcoming quarterly results (Q3 FY27), as well as margin effects from the improved process technology.
110% PAT Growth in Q1 FY27; 100,000 TPA Dimethyl Ether Plant Commissioned
Balaji Amines reported a robust Q1 FY27 with consolidated revenue growing 25.7% YoY to ₹461 crore and PAT doubling to ₹78 crore. The performance was bolstered by a significant margin expansion, with EBITDA margins rising to 26% from 17% in the same quarter last year. A key operational milestone was the commissioning of India's first commercial-scale 100,000 TPA Dimethyl Ether (DME) plant. The company remains debt-free on a standalone basis while aggressively investing ₹566.66 crore in ongoing capital projects (CWIP).
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has successfully transitioned its 100,000 TPA DME plant from development to operations and achieved a sharp recovery in profitability margins.
ஏன் இது முக்கியம்The DME plant marks an entry into clean fuels and aerosol propellants, diversifying the revenue base beyond traditional amines. The high CWIP indicates a strong growth pipeline for the next 12-18 months.
Q1 FY27 PAT Growth (YoY): 110.19%DME Plant Capacity: 100,000 TPATotal CWIP: ₹566.66 கோடிCWIP vs Net Worth: 31.76%EBITDA Margin (Q1 FY27): 26%
📅 குறுகிய காலம்The stock is likely to react positively to the doubling of PAT and the successful commissioning of the major DME project.
📈 நீண்ட காலம்Structural growth is supported by import substitution strategies and expansion into high-value specialty chemicals like HCN and NaCN through its subsidiary BSCL.
⚠ அபாய எச்சரிக்கைகள்
Raw material price volatility
Global macroeconomic headwinds affecting export demand
👀 கவனிக்க வேண்டியவை
Investors should monitor the capacity utilization and revenue contribution of the newly commissioned DME plant and track the commissioning of the NMM and Acetonitrile projects scheduled for later in FY27.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
110% YoY PAT Growth in Q1FY27; 100,000 TPA DME Plant Commissioned
Balaji Amines reported a strong Q1 FY27 with consolidated revenue growing 25.6% YoY to ₹461 crore and PAT jumping 110.8% to ₹78 crore. EBITDA margins expanded significantly to 26% from 17% a year ago, driven by improved demand and operational efficiencies. The company successfully commissioned India's first 100,000 TPA Dimethyl Ether (DME) plant, marking a strategic entry into alternate fuels. Despite a 21.7% YoY drop in total sales volume to 21,587 MT, profitability improved sharply due to better realizations and product mix.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has transitioned from a period of margin pressure to high profitability (26% EBITDA margin) and operationalized its first major diversification into alternate fuels (DME).
ஏன் இது முக்கியம்The sharp margin recovery and successful commissioning of the DME plant indicate a shift towards higher-value specialty products and import substitution, reducing reliance on volatile commodity amine cycles.
📅 குறுகிய காலம்The stock is likely to react positively to the significant earnings beat and margin expansion, reflecting improved operational health.
📈 நீண்ட காலம்Structural growth is supported by the ₹750 crore expansion into cyanide chemistry and downstream derivatives, positioning the company as a key player in import substitution for pharma and agrochemicals.
⚠ அபாய எச்சரிக்கைகள்
21.7% YoY decline in sales volumes
Sensitivity to raw material price volatility
Execution risk for large-scale greenfield projects in FY27
👀 கவனிக்க வேண்டியவை
Monitor the capacity utilization and revenue contribution from the newly commissioned DME plant and the execution timeline of the ₹750 crore expansion at Balaji Speciality Chemicals scheduled for FY27.
Balaji Amines reported a robust start to FY27, with consolidated revenue growing 27.2% YoY to ₹455.93 Cr. Net profit surged 113.8% YoY to ₹78.12 Cr, reflecting a significant recovery in margins compared to the previous year. The core Amines & Specialty Chemicals segment drove performance, contributing ₹452.89 Cr to the top line. This sharp growth in profitability follows a period of moderated demand in the pharma and agrochemical sectors.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has delivered a significant earnings beat with triple-digit profit growth and substantial margin expansion compared to the same quarter last year.
ஏன் இது முக்கியம்The results indicate a strong operational turnaround and potential recovery in end-user industries like pharmaceuticals and agriculture, which had previously seen moderated demand.
Consolidated Revenue (Q1 FY27): ₹455.93 கோடிConsolidated PAT (Q1 FY27): ₹78.12 கோடிYoY PAT Growth: 113.8%Q1 வருவாய் vs TTM வருவாய்: ~32%Consolidated EPS: ₹23.13
📅 குறுகிய காலம்The stock is likely to react positively in the short term due to the strong earnings surprise and sharp improvement in profitability metrics.
📈 நீண்ட காலம்Long-term value depends on the successful commissioning of new plants (DME, NMM) and the completion of Unit 4 expansions by FY26 to diversify the product mix into advanced chemicals.
⚠ அபாய எச்சரிக்கைகள்
Raw material price volatility due to import dependency
Cyclical demand from pharmaceutical and agrochemical sectors
👀 கவனிக்க வேண்டியவை
Monitor the execution timeline of Unit 4 Greenfield Phase 2 & 3 expansions scheduled for FY26 completion, which are critical for future volume growth. Watch for management commentary regarding the sustainability of these improved margins and demand recovery in the agrochemical sector.
Balaji Amines Sets July 3, 2026, as Record Date for ₹11 Final Dividend
Balaji Amines Limited has officially fixed July 3, 2026, as the record date to determine eligibility for a final dividend of ₹11 per equity share for the financial year 2025-26. The dividend, which represents 550% of the ₹2 face value, is subject to shareholder approval at the Annual General Meeting (AGM) scheduled for July 10, 2026. Eligible shareholders will receive the payment within 30 days of the AGM approval. This announcement follows the initial board recommendation made on May 13, 2026.
முக்கிய அம்சங்கள்
Final dividend recommended at ₹11 per equity share with a face value of ₹2 each.Record date for determining dividend entitlement is fixed as Friday, July 3, 2026.Annual General Meeting (AGM) is scheduled to be held on Friday, July 10, 2026.Dividend payment will be completed within 30 days from the date of the AGM, subject to approval.The dividend applies to both dematerialized and physical shareholdings as of the record date.
👀 கவனிக்க வேண்டியவை
Investors interested in the dividend should ensure they hold the stock before the ex-dividend date to be eligible for the ₹11 per share payout.
Balaji Amines FY26 Revenue at ₹1,454 Cr; Recommends ₹11 Dividend & Outlines Major Capex
Balaji Amines reported a consolidated revenue of ₹1,454 crore and a PAT of ₹169 crore for FY26, with a strong Q4 recovery showing 62% YoY PAT growth. The company remains debt-free at the standalone level and has recommended a dividend of ₹11 per share. Management has provided a positive outlook with 10-15% volume growth guidance for FY27, supported by the commissioning of new plants like the 1,00,000 TPA DME facility and upcoming projects in the EDA and Cyanide chains.
முக்கிய அம்சங்கள்
Reported FY26 consolidated revenue of ₹1,454 crore and PAT of ₹169 crore, with Q4 EBITDA margins reaching 25%.Recommended a dividend of ₹11 per share for the seventh consecutive year while maintaining a debt-free standalone balance sheet.Commissioned India's first Electronic Grade DMC plant for EV batteries and a 1,00,000 TPA DME plant in Q1FY27.Guided for 10-15% volume growth in FY27 and 20-30% medium-term growth as BSCL Unit I and II projects come online by March 2027.Focusing on high-value import substitutes including EDA, DETA, TETA, and Sodium Cyanide to drive future margins.
👀 கவனிக்க வேண்டியவை
Investors should consider the stock a strong long-term play on chemical import substitution and the EV battery supply chain. The combination of debt-free expansion and clear volume growth guidance makes it a compelling watch as new capacities stabilize.
Balaji Amines Q4 FY26 PAT Jumps 62% YoY to ₹65 Cr; EBITDA Margins Expand to 25%
Balaji Amines reported a strong Q4 FY26 with consolidated revenue growing 12% YoY to ₹403 crore and PAT rising significantly to ₹65 crore. The company achieved a robust EBITDA margin of 25%, driven by better operating leverage and a favorable product mix. Management has guided for a 25-30% volume growth by the end of 2027, supported by a massive ₹750 crore expansion in specialty chemicals. The company remains standalone debt-free and is focusing on import substitution for high-value products like Dimethyl Ether and Acetonitrile.
முக்கிய அம்சங்கள்
Q4 FY26 consolidated revenue rose 12% YoY to ₹403 crore with EBITDA margins expanding to 25% from 19% YoY.Management expects 25-30% volume growth by FY27-end as new capacities for DME, NMM, and ACN come online.Ongoing ₹750 crore expansion at Balaji Specialty Chemicals targeting HCN and EDTA derivatives with Mega Project status.Standalone entity remains debt-free with consolidated net worth reaching ₹2,152 crore as of March 2026.Targeting a revenue milestone of ₹2,000 crore by FY28 driven by specialty chemical ramp-ups.
👀 கவனிக்க வேண்டியவை
Investors should monitor the timely commissioning of the DME and Balaji Specialty expansion projects, which are critical for achieving the targeted 25-30% volume growth. The significant margin expansion suggests improved pricing power and operational efficiency that warrants a positive outlook.
Balaji Amines has commenced commercial production at its new 1,00,000 TPA Dimethyl Ether (DME) facility in Solapur, Maharashtra, making it the first commercial-scale manufacturer of DME in India. The product serves as a clean alternative fuel that can be blended with LPG up to 8% under new BIS standards, potentially reducing India's import dependency. Beyond DME, the company is aggressively expanding into the EV battery chemical space, being the sole Indian manufacturer of Dimethyl Carbonate (DMC) with a 15,000 MTPA capacity. This move diversifies the company's portfolio into high-growth energy and electronic-grade chemical sectors.
முக்கிய அம்சங்கள்
Successfully commissioned India's first commercial DME plant with an annual capacity of 1,00,000 Metric Tonnes.DME is approved for blending with LPG up to 8% as per new BIS standards, targeting the domestic fuel and aerosol markets.Company remains the sole Indian manufacturer of Dimethyl Carbonate (DMC) with 15,000 MTPA capacity for EV battery electrolytes.Strategic focus on Electronic Grade N-Methyl Pyrrolidone (NMP) to supply upcoming domestic EV battery Giga factories.The DME project utilized advanced technology sourced from a foreign partner to ensure high-efficiency production.
👀 கவனிக்க வேண்டியவை
Investors should track the adoption rate of DME blending by Oil Marketing Companies and the utilization levels of the new 1,00,000 TPA capacity. The company's unique position as a sole manufacturer in both DME and DMC segments offers a significant competitive moat in the specialty chemicals sector.
Balaji Amines Q4FY26 PAT Surges 63% YoY to ₹65 Cr; EBITDA Margins Expand to 25%
Balaji Amines reported a robust Q4FY26 with consolidated revenue growing 11.7% YoY to ₹403 crore. Profitability saw a significant boost as PAT jumped 63.3% YoY to ₹65 crore, driven by substantial EBITDA margin expansion from 19% to 25%. Total sales volumes increased to 27,341 MT, supported by stable demand in specialty chemicals and amines. The company is also progressing on a major ₹750 crore expansion in its subsidiary and expects to commission its Dimethyl Ether plant in Q1FY27.
முக்கிய அம்சங்கள்
Consolidated PAT increased by 63.3% YoY and 108.3% QoQ to ₹65 crore in Q4FY26.EBITDA margins expanded to 25% in Q4FY26 from 19% in Q4FY25 and 18% in Q3FY26.Total sales volume grew to 27,341 MT, with Specialty Chemicals accounting for 10,660 MT.Announced a ₹750 crore expansion project in subsidiary Balaji Speciality Chemicals for HCN and Sodium Cyanide.Dimethyl Ether (DME) plant (1,00,000 TPA) and new Acetonitrile plant expected to commission in H1FY27.
👀 கவனிக்க வேண்டியவை
The significant margin recovery and strong volume growth signal a turnaround in operational efficiency. Investors should monitor the timely commissioning of the DME and Acetonitrile plants in early FY27, which are expected to be the next growth catalysts.
Balaji Amines Q4FY26 PAT Surges 62% YoY to ₹65 Cr; EBITDA Margins Expand to 25%
Balaji Amines reported a strong performance for Q4FY26, with consolidated revenue growing 11.6% YoY to ₹403 crore. The company witnessed significant margin expansion, with EBITDA margins rising to 25% from 19% in the previous year, resulting in a 62.5% jump in Net Profit to ₹65 crore. Management highlighted a robust growth pipeline, including a ₹750 crore 'Mega Project' expansion in its subsidiary and several new plants scheduled for commissioning in FY27. Despite minor geopolitical disruptions in March, the company maintained stable operations and sales volumes.
முக்கிய அம்சங்கள்
Consolidated Q4FY26 PAT rose 62.5% YoY to ₹65 crore, while EBITDA increased 50% to ₹102 crore.EBITDA margins improved significantly to 25% in Q4FY26 compared to 19% in Q4FY25.Total sales volume for the quarter increased to 27,341 MT, with Specialty Chemicals contributing 10,660 MT.Announced a ₹750 crore expansion in subsidiary Balaji Speciality Chemicals for HCN and EDTA products with 'Mega Project' status.DME and Acetonitrile plants are on track for commissioning in Q1 and Q2 of FY2026-27 respectively.
👀 கவனிக்க வேண்டியவை
Investors should take note of the sharp recovery in margins and the aggressive ₹750 crore expansion plan which signals strong future capacity. The stock remains a key play in the amines sector with multiple growth triggers lined up for FY27.
Balaji Amines FY26 PAT Rises 6% to ₹165.5 Cr; Recommends ₹11 Dividend
Balaji Amines reported a steady standalone performance for FY26, with revenue from operations reaching ₹1,291.54 crore. The company witnessed a strong surge in Q4 FY26 profitability, with PAT jumping 56.2% year-on-year to ₹61.87 crore compared to ₹39.60 crore in the same quarter last year. For the full year, standalone PAT increased by 6% to ₹165.53 crore. Reflecting this performance, the board has recommended a final dividend of ₹11 per equity share (550% of face value).
முக்கிய அம்சங்கள்
Recommended a final dividend of ₹11 per equity share for FY2025-26.Q4 FY26 standalone PAT surged 56.2% YoY to ₹61.87 crore.Full-year FY26 standalone revenue grew to ₹1,291.54 crore from ₹1,273.59 crore in FY25.Annual standalone EPS increased to ₹51.09 from ₹48.21 in the previous year.Cash and cash equivalents at year-end improved significantly to ₹73.62 crore from ₹38.49 crore.
👀 கவனிக்க வேண்டியவை
The strong Q4 recovery and healthy dividend payout indicate operational resilience; investors should maintain a positive outlook while monitoring consolidated performance.
Balaji Amines Q4 FY26 Net Profit Jumps 56% YoY to ₹61.87 Cr; ₹11 Dividend Declared
Balaji Amines reported a robust performance for Q4 FY26, with standalone net profit surging 56.2% YoY to ₹61.87 crore. Quarterly revenue from operations grew 12.5% YoY to ₹361.77 crore, while full-year FY26 revenue stood at ₹1,291.54 crore. The company demonstrated improved profitability with EPS rising to ₹19.09 for the quarter compared to ₹12.22 in the previous year. Additionally, the board recommended a substantial final dividend of ₹11 per share, signaling strong cash flow and management confidence.
முக்கிய அம்சங்கள்
Standalone Q4 Net Profit increased to ₹6,186.60 Lakhs from ₹3,960.09 Lakhs YoY.Recommended a final dividend of ₹11 per equity share (550% on face value of ₹2).Full-year FY26 Standalone Revenue reached ₹1,29,154.47 Lakhs vs ₹1,27,359.23 Lakhs in FY25.Quarterly Earnings Per Share (EPS) improved significantly to ₹19.09 from ₹12.22 YoY.Cash and cash equivalents increased to ₹7,362.07 Lakhs as of March 31, 2026, up from ₹3,849.24 Lakhs.
👀 கவனிக்க வேண்டியவை
The strong recovery in net profit and the healthy dividend payout make this a positive result; investors should monitor the sustainability of these margins in upcoming quarters. Existing shareholders may hold for the dividend and growth potential in the specialty chemicals space.
Balaji Amines Restarts Production of Ammonia-Based Products as Supply Chain Improves
Balaji Amines has announced the gradual restart of production for Ammonia-based products, including Methylamines and Ethylamines, following a period of partial non-operation. The disruption was caused by geopolitical conflicts in the Middle East affecting Ammonia supply since March 12, 2026. While the global supply chain remains dynamic, the company reports that availability is improving. Management is actively seeking alternative suppliers to ensure long-term raw material stability and mitigate future risks.
முக்கிய அம்சங்கள்
Gradual restart of production for Methylamines, Ethylamines, and their derivatives.Recovery from supply chain disruptions caused by Middle East geopolitical conflicts since March 2026.Plants were previously in a partially non-operational phase due to Ammonia shortages.Company is engaging with alternative suppliers to diversify raw material procurement.
👀 கவனிக்க வேண்டியவை
Investors should monitor the pace of production ramp-up and the impact of raw material pricing on margins. This restart reduces the risk of prolonged revenue loss from the previously non-operational units.
Balaji Amines Shuts Plants Due to Ammonia Supply Disruption Amid Middle East Conflict
Balaji Amines has reported a significant disruption in its supply chain due to the ongoing Middle East conflict, which has severely impacted global shipping and logistics. Key suppliers of Ammonia, a critical raw material for the company, have invoked Force Majeure clauses following a shortage of Liquefied Natural Gas (LNG). As a result, several of the company's manufacturing plants are currently non-operational, affecting the production of Methylamines and Ethylamines. While the company is exploring alternative supply sources, the total financial and operational impact remains unquantifiable at this stage.
முக்கிய அம்சங்கள்
Middle East conflict has led to Force Majeure invocations by key Ammonia suppliers.Shortage of LNG has halted Ammonia production for several Indian manufacturers.Multiple manufacturing plants of Balaji Amines are currently non-operational due to raw material unavailability.Production of core products including Methylamines, Ethylamines, and derivatives is significantly affected.The company is unable to estimate the exact financial impact of the shutdown at this time.
👀 கவனிக்க வேண்டியவை
Investors should prepare for a potential decline in short-term revenue and margins due to plant shutdowns. It is advisable to monitor the duration of the Force Majeure and the company's progress in securing alternative Ammonia supplies.
Balaji Amines Q3FY26: Revenue Up 4.9% YoY to ₹336 Cr; EBITDA Margins Improve to 18.3%
Balaji Amines reported a mixed Q3FY26 with consolidated revenue growing 4.9% YoY to ₹336.29 crore, though it declined 3.26% sequentially. While EBITDA grew 15.12% YoY to ₹61.67 crore with margins expanding to 18.34%, PAT saw a slight YoY dip of 1.22% to ₹30.76 crore. Total sales volumes increased to 25,894 MT from 24,097 MT YoY, driven by steady demand in specialty chemicals and amines. The company is aggressively pursuing a ₹750 crore expansion in its subsidiary and expects several new plants to commission in FY27.
முக்கிய அம்சங்கள்
Consolidated Revenue grew 4.9% YoY to ₹336.29 Cr, supported by a volume increase to 25,894 MT.EBITDA margins improved to 18.34% from 16.71% YoY, despite a 7.78% QoQ drop in EBITDA.PAT for Q3FY26 stood at ₹30.76 Cr, reflecting a 17.09% sequential decline due to higher tax and depreciation.Methylamines capacity successfully expanded to 88,000 TPA; ₹750 Cr expansion underway in subsidiary for HCN and EDTA products.Standalone entity remains zero-debt, with all new projects funded through internal accruals.
👀 கவனிக்க வேண்டியவை
Investors should monitor the progress of the ₹750 crore expansion and the commissioning of the DME plant in FY27, which are key growth catalysts. The current margin recovery is encouraging, but sequential PAT pressure warrants a cautious hold until volume growth translates to bottom-line stability.
Balaji Amines Q3FY26 Consolidated PAT at ₹31 Cr; ₹750 Cr Expansion Underway
Balaji Amines reported a consolidated revenue of ₹336.29 crore for Q3FY26, a slight decline from ₹347.61 crore in the previous quarter. Net profit for the quarter stood at ₹30.76 crore, down from ₹37.10 crore in Q2FY26, with EBITDA margins contracting to 18.34%. Despite near-term pressure from the pharma and agrochemical segments, the company is moving ahead with a ₹750 crore expansion plan in its subsidiary, which has received 'Mega Project' status. Several new plants, including DME and Acetonitrile, are expected to be commissioned in FY 2026-27.
முக்கிய அம்சங்கள்
Consolidated PAT for Q3FY26 decreased to ₹30.76 crore from ₹37.10 crore in Q2FY26.EBITDA margin stood at 18.34% for the quarter, compared to 19.24% in the previous quarter.Total sales volume for Q3FY26 was 25,894.09 MT, with Specialty Chemicals accounting for 9,678.27 MT.Announced a ₹750 crore phased expansion in subsidiary Balaji Speciality Chemicals for products like Sodium Cyanide and EDTA.The company maintains a zero-debt status on a standalone basis, funding projects through internal accruals.
👀 கவனிக்க வேண்டியவை
Investors should monitor the margin recovery and the progress of the ₹750 crore capex, as significant growth is tied to the FY27 commissioning of new plants. The current slowdown in the pharmaceutical and agrochemical sectors remains a key headwind to watch.
Balaji Amines Q3 Consolidated PAT Declines 17% QoQ to ₹30.76 Crore
Balaji Amines reported a mixed performance for Q3 FY26, with consolidated revenue growing 5.9% YoY to ₹331.30 crore but declining 2.7% sequentially. Profitability faced significant pressure as consolidated PAT fell 17% QoQ to ₹30.76 crore, impacted by higher raw material costs and increased finance charges. The core Amines & Speciality Chemicals segment remains the primary driver, contributing over 97% of total revenue. On a nine-month basis, PAT stands at ₹104.39 crore, down from ₹118.15 crore in the previous year, indicating a challenging margin environment.
முக்கிய அம்சங்கள்
Consolidated Revenue from operations stood at ₹331.30 crore, a 5.9% increase compared to ₹312.73 crore in Q3 FY25.Consolidated Net Profit (PAT) dropped to ₹30.76 crore, down 17% from ₹37.10 crore in the preceding quarter.Earnings Per Share (EPS) for the quarter decreased to ₹9.49 from ₹10.24 in the same period last year.The Amines & Speciality Chemicals segment reported a profit before tax of ₹41.99 crore, down from ₹49.38 crore in Q2 FY26.Total consolidated expenses for the quarter rose to ₹290.31 crore, reflecting margin compression compared to the previous quarter.
👀 கவனிக்க வேண்டியவை
Investors should exercise caution due to the significant sequential decline in profitability and margin pressure. Monitor raw material price trends and volume growth in the speciality chemicals segment before making new entries.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
